In a filing, CRISPR Therapeutics AG revealed its Officer Samarth Kulkarni acquired Company’s shares for reported $2.35 million on Feb 18 ’25. In the deal valued at $52.22 per share,45,000 shares were bought.
Then, Kulkarni Samarth sold 15,000 shares, generating $826,564 in total proceeds. Upon selling the shares at $55.10, the Chief Executive Officer now owns 181,540 shares.
Before that, Kulkarni Samarth sold 30,000 shares. CRISPR Therapeutics AG shares valued at $1,668,678 were divested by the Chief Executive Officer at a price of $55.62 per share. As a result of the transaction, Kulkarni Samarth now holds 196,540 shares, worth roughly $10.26 million.
Evercore ISI upgraded its CRISPR Therapeutics AG [CRSP] rating to an Outperform from a an In-line in a research note published on February 14, 2025; the price target was increased to $99 from $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Hold”. H.C. Wainwright began covering CRSP with “Buy” recommendation on February 03, 2025. Needham maintained its rating on August 06, 2024. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Tuesday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 5.03% to $52.22. Over the last five days, the stock has gained 32.50%. CRISPR Therapeutics AG shares have risen nearly 32.67% since the year began. Nevertheless, the stocks have fallen -33.93% over the past one year. While a 52-week high of $91.10 was reached on 02/18/25, a 52-week low of $36.52 was recorded on 01/13/25. SMA at 50 days reached $42.75, while 200 days put it at $49.52.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 50.39, which if violated will result in even more drops to 48.57. On the upside, there is a resistance level at 54.67. A further resistance level may holdings at 57.13. The Relative Strength Index (RSI) on the 14-day chart is 73.78, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 5.93, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 18.10%. Stochastics %K at 80.56% indicates the stock is a selling.
The most recent change occurred on August 02, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
